Economist Podcasts Square dealing: Jiang Zemin dies
Dec 1, 2022
James Miles, a China writer at large for The Economist, and Anna Nichols, managing editor at the Economist Intelligence Unit, delve into Jiang Zemin’s controversial legacy. They discuss the stark contrast between Jiang's vibrant leadership style and Xi Jinping's more reserved approach. With ongoing protests in China, they explore political repression alongside economic reforms. The duo also highlights promising advances in Alzheimer’s treatment and examines global rising costs of living, including insights into the world's most expensive cities.
AI Snips
Chapters
Transcript
Episode notes
Alzheimer's Drug Development
- Alzheimer's drug development has historically been challenging, with billions spent and few successes.
- Lecanemab's results are considered more conclusive, potentially validating the amyloid hypothesis.
Amyloid Hypothesis
- The amyloid hypothesis posits that sticky amyloid plaques cause Alzheimer's.
- Lecanemab targets these plaques, attracting the immune system to clear them.
Lecanemab's Challenges
- Widespread availability of lecanemab is uncertain due to side effects like brain swelling and bleeding.
- Questions remain about the drug's real-world effectiveness and cost.